(Total Views: 338)
Posted On: 04/16/2017 12:17:41 PM
Post# of 15624
It's becoming very clear now that there is ongoing research efforts in the treatment of BOTH myeloma and melanoma . Thank you for the myeloma study link: http://www.prnewswire.com/news-releases/owc-p...24291.html
MELANOMA:
As moxaman pointed out melanoma is a much more common form of skin cancer and the potential rewards to a company that comes up with a successful treatment will be HUGE!!!
We know that in February Dr. Sharon Rozenblat joined the company in an advisory capacity. It is no coincidence that she earned her doctorate in Biochemistry and Cell Biology from Bar Ilan University in Israel, where her research focused on botanical components as therapeutic agents for melanoma.
https://investorshangout.com/post/view?id=448...z4eQYOL2Oi
So shortly after Dr. Rozenblat's appointment, the following PR on March 21 is in my opinion very revealing:
As a result of the promising results of our psoriasis tests, our Chairman and CEO, Mr. Mordechai Bignitz, has directed OWC's scientific team to submit an operating plan within 60 to 90 days to conduct double-blind efficacy tests of our cannabinoid-based topical cream on other skin disorders and conditions.
http://www.prnewswire.com/news-releases/owc-p...97214.html
Without coming right out and saying so, I think that Mr. Bignitz is saying that tests on melanoma are definitely on the table. The puzzle is fitting together nicely and it's great to know that they not only have a top notch medical team behind the research, but they also have ambition!!
MELANOMA:
As moxaman pointed out melanoma is a much more common form of skin cancer and the potential rewards to a company that comes up with a successful treatment will be HUGE!!!
We know that in February Dr. Sharon Rozenblat joined the company in an advisory capacity. It is no coincidence that she earned her doctorate in Biochemistry and Cell Biology from Bar Ilan University in Israel, where her research focused on botanical components as therapeutic agents for melanoma.
https://investorshangout.com/post/view?id=448...z4eQYOL2Oi
So shortly after Dr. Rozenblat's appointment, the following PR on March 21 is in my opinion very revealing:
As a result of the promising results of our psoriasis tests, our Chairman and CEO, Mr. Mordechai Bignitz, has directed OWC's scientific team to submit an operating plan within 60 to 90 days to conduct double-blind efficacy tests of our cannabinoid-based topical cream on other skin disorders and conditions.
http://www.prnewswire.com/news-releases/owc-p...97214.html
Without coming right out and saying so, I think that Mr. Bignitz is saying that tests on melanoma are definitely on the table. The puzzle is fitting together nicely and it's great to know that they not only have a top notch medical team behind the research, but they also have ambition!!
(9)
(0)
